Evaluation of Capillary Blood Collection Devices (Mitra® and HemaPEN®)

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Jun 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two blood collection devices called Mitra® and HemaPEN®, which are typically used in other areas of medicine but are being tested for children with a condition called phenylketonuria (PKU). PKU is a metabolic disorder that requires regular monitoring of a substance called phenylalanine in the blood. The goal of this trial is to see if these devices make it easier for families to collect blood samples at home and send them by mail, which can help with the frequent testing needed for managing PKU.

To be eligible for this trial, children must be between 3 months and 18 years old and diagnosed with PKU or a related condition. Their parents or guardians need to be part of the social security system and must agree to participate in the study. If families choose to take part, they can expect a more convenient way to manage their child’s health by using these devices at home instead of visiting a clinic for blood tests. This could make life a little easier for families dealing with the challenges of regular health monitoring.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 3 months to 18 years
• • suffering from phenylketonuria or hyperphenylalaninemia
• • who have had a capillary and blood test including a phenylalanine assay at CHUGA
• • Whose parents or legal guardians are affiliated to the social security system.
• • For whom parents or legal guardians have not objected to the MitrAlanine study.
• Exclusion Criteria:
• • Parents or legal guardians opposed to the MitrAlanine study